24 May 2013
Keywords: cv, therapeutics, shares, slump, analyst, note, been
Article | 03 June 2002
Shares in CV Therapeutics have been hit hard by a Morgan Stanley reportclaiming that the company's drug for angina, ranolazine, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
6 December 2001
23 May 2013
© 2013 thepharmaletter.com